A Phase 1, Randomized, Single Blind Study to Evaluate the Pharmacokinetics, Pharmacodynamics, and Safety of an Oral Contraceptive Containing Norethindrone and Ethinyl Estradiol When Co-administered With GSK1322322 in Healthy Adult Women of Childbearing Age Who Are of Non-Childbearing Potential Due to Surgical Sterilization or IUD Placement.

Trial Profile

A Phase 1, Randomized, Single Blind Study to Evaluate the Pharmacokinetics, Pharmacodynamics, and Safety of an Oral Contraceptive Containing Norethindrone and Ethinyl Estradiol When Co-administered With GSK1322322 in Healthy Adult Women of Childbearing Age Who Are of Non-Childbearing Potential Due to Surgical Sterilization or IUD Placement.

Withdrawn prior to enrolment
Phase of Trial: Phase I

Latest Information Update: 30 Jan 2015

At a glance

  • Drugs Lanopepden (Primary) ; Ethinylestradiol/norethisterone
  • Indications Bacterial infections; Pregnancy
  • Focus Pharmacokinetics
  • Sponsors GlaxoSmithKline
  • Most Recent Events

    • 27 Jan 2015 Status changed from not yet recruiting to withdrawn prior to enrolment, as reported by ClinicalTrials.gov.
    • 11 Apr 2014 Planned End Date changed from 1 Mar 2015 to 1 May 2015 as reported by ClinicalTrials.gov.
    • 11 Apr 2014 Planned initiation date changed from 1 Jul 2014 to 1 Aug 2014 as reported by ClinicalTrials.gov
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top